CITIUS ONCOLOGY, INC.

CTOR · Nasdaq · SIC 2834: Pharmaceutical Preparations
75
SEC Filings

Business Summary

PART I Business Overview The Company, headquartered in Cranford, New Jersey, is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. The Companys strategy centers on achieving a market leading position by advancing innovative therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs w...

Next Earnings

Q2 FY2026 — expected 2026-09-14

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionCTORdiscussed_in_filing Artificial Intelligence
topic_mentionCTORdiscussed_in_filing Cybersecurity
topic_mentionCTORdiscussed_in_filing Trusted Computing
topic_mentionCTORdiscussed_in_filing Blockchain & Crypto
topic_mentionCTORdiscussed_in_filing Regulation
topic_mentionCTORdiscussed_in_filing Healthcare & Bio
topic_mentionCTORdiscussed_in_filing Platform & Ecosystem
topic_mentionCTORdiscussed_in_filing Artificial Intelligence
topic_mentionCTORdiscussed_in_filing Cybersecurity
topic_mentionCTORdiscussed_in_filing Trusted Computing
topic_mentionCTORdiscussed_in_filing Blockchain & Crypto
topic_mentionCTORdiscussed_in_filing Regulation
topic_mentionCTORdiscussed_in_filing Healthcare & Bio
topic_mentionCTORdiscussed_in_filing Platform & Ecosystem
topic_mentionCTORdiscussed_in_filing Artificial Intelligence
topic_mentionCTORdiscussed_in_filing Cybersecurity
topic_mentionCTORdiscussed_in_filing Trusted Computing
topic_mentionCTORdiscussed_in_filing Blockchain & Crypto
topic_mentionCTORdiscussed_in_filing Regulation
topic_mentionCTORdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-12-232025-09-300001213900-25-125331EDGAR61K words
2024-12-272024-09-300001213900-24-113150EDGAR
2024-04-162023-12-310001493152-24-014850EDGAR
2023-04-172022-12-310001493152-23-012545EDGAR

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-02-132025-12-310001213900-26-015877EDGAR15K words
2025-08-122025-06-300001213900-25-074992EDGAR
2025-05-142025-03-310001213900-25-043359EDGAR
2025-02-142024-12-310001213900-25-014320EDGAR
2024-08-092024-06-300001493152-24-030991EDGAR
2024-05-202024-03-310001493152-24-020783EDGAR
2023-11-202023-09-300001493152-23-042170EDGAR
2023-08-162023-06-300001493152-23-029131EDGAR
2023-05-152023-03-310001493152-23-017394EDGAR
2022-11-282022-09-300001493152-22-033847EDGAR

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-310001213900-26-037501EDGAR3K words
2026-03-100001213900-26-025464EDGAR
2026-03-040001213900-26-023440EDGAR
2026-02-130001213900-26-015894EDGAR
2025-12-230001213900-25-125418EDGAR
2025-12-100001213900-25-120197EDGAR
2025-12-010001213900-25-116764EDGAR
2025-10-270001213900-25-102625EDGAR
2025-10-230001213900-25-101737EDGAR
2025-09-190001213900-25-089615EDGAR

75 total filings indexed. 51 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001851484
TickerCTOR
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: c2ddd0a5dd7a69f39450a0c803f16b579a4e67bb1efec005cd88dd68a89b1038
parent: eff2d9eaa794f7b2fc987ed5ef2cd6180e335c35684ece6031b0282ddac12401
content hash: 841ff9101328e428d6993e4ef27d6b8dd3a034cd6238ff1a2e0eedf93090333e
signed: 2026-04-13T04:44:32.390Z
sources: 14 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf